KLK2 Antibody

說明書

中文名稱：

KLK2兔多克隆抗體
貨號：

CSB-PA039286
規格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA039286(KLK2 Antibody) at dilution 1/100, on the right is treated with synthetic peptide. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using CSB-PA039286(KLK2 Antibody) at dilution 1/100, on the right is treated with synthetic peptide. (Original magnification: ×200)
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

P20151
基因名：

KLK2
別名：

Glandular kallikrein 2 antibody; Glandular kallikrein-1 antibody; hGK 1 antibody; hGK-1 antibody; hK2 antibody; Kallikrein 2 prostatic antibody; Kallikrein related peptidase 2 antibody; kallikrein, glandular antibody; Kallikrein, prostatic antibody; Kallikrein-2 antibody; KLK 2 antibody; Klk-2 antibody; Klk2 antibody; KLK2_HUMAN antibody; KLK2A 2 antibody; KLK2A2 antibody; MGC12201 antibody; Tissue kallikrein 2 antibody; Tissue kallikrein-2 antibody; Ton antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Synthetic peptide of Human KLK2
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產品提供形式：

Liquid
應用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
基因功能參考文獻：
1. glycosylation changes the enzymatic activity of KLK2 in a drastically substrate-dependent manner. PMID: 26582203
2. The results indicated that W-hK2 had a defect in cellular trafficking due to its misfolding and that it activated the unfolded protein response, suggesting a mechanism to explain the association of the T allele with higher prostate cancer risk. PMID: 25847286
3. miR-378 was predicted to target both KLK2 and KLK4 and downregulated levels detected in prostate cancer patients. PMID: 25153390
4. The differential regulation of alternative transcripts (using KLK2, KLK3 and KLK4 as models) by androgens and anti-androgens as an indicator of prostate cancers, was investigated. PMID: 25153393
5. Structure-function analyses of KLK2 establish the 99-loop as master regulator of its activity. PMID: 25326387
6. Predictions based on levels of four kallikrein markers, including KLK2, in blood distinguish between pathologically insignificant and aggressive disease after radical prostatectomy with good accuracy. PMID: 23683475
7. Alteration of cellular junctions in benign prostatic hyperplasia could contribute to the presence of luminal epithelial secreted proteins prostate specific antigen (PSA)2 and and KLK2 in the stromal compartment. PMID: 24711254
8. we present the first evidence that KLK2 can also function as an androgen receptor modulator that may modulate cell growth after the development of castration-resistant prostate cancer PMID: 24122203
9. Associations observed in young, healthy men between the seminal plasma and serum concentrations of hK2 and PSA and several genetic variants in KLK2 and KLK3 could be useful to refine models of PSA cutoff values in prostate cancer testing. PMID: 24270797
10. Genetic variants at ATF7IP and KLK2 contribute to the variance of %fPSA. PMID: 23359319
11. Two SNPs, in beta-microseminoprotein at and in kallikrein-related peptidase 2 at, are associated with PCA3 score at genome-wide significance level PMID: 23555189
12. TK promotes vessel growth by increasing the number of EPCs and enhancing their functional properties through the kinin B(2) receptor-Akt signaling pathway. PMID: 22435954
13. An exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer was found to be less likely associated with low Gleason score morphology. PMID: 21178268
14. we identifiedand genotyped novel single-nucleotide polymorphisms in cancer cases and controls which verified prior associations in KLK2 and in MSMB (but not in KLK3) with prostate cancer PMID: 20424135
15. Data show six non-synonymous amino acid or frame shift changes in the KLK3 gene and three changes in each of the neighboring genes, KLK15 and KLK2. PMID: 19823874
16. The identification of unusual mRNA splice variants of the KLK2 and KLK3 genes that result from inclusion of intronic sequences adjacent to the first exon. PMID: 11834722
17. Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. PMID: 12124798
18. kallikrein expression in nipple aspirate fluid- ethnic variation PMID: 12209605
19. Measurements of free prostate specific antigen and hK2 improve on our ability to counsel patients prior to treatment as to their risk of biochemical recurrence PMID: 16152616
20. An additional serum marker for the detection of prostatic cancer. PMID: 16388506
21. a role for the KLK2 gene in prostate cancer susceptibility PMID: 17085659
22. results imply that prostate cancer risk is associated with androgen receptor(AR)-CAG repeat and kallikrein-2 polymorphisms in Indian population but no unambiguous association was observed with PSA and AR-GGN repeat polymorphism PMID: 17257635
23. role of kallikrein gene 2 and 3 variant SNPs in the etiology of prostate cancer among men of European ancestry PMID: 17593395
24. %fPSA and hK2 add important predictive value in older men and much closer to diagnosis PMID: 17657743
25. The two novel ETV4 fusion partners possess as predominant common characteristics androgen-induction and prostate-specific expression. PMID: 18451133
26. Recombinant hK2 activates ERK1/2 signaling of prostate cancer cell lines, which express both PAR1 and PAR2. PMID: 18567807
27. adding free PSA and human kallikrein 2 to standard pretreatment risk-assessment models to predict biochemical recurrence after radical prostatectomy for prostate cancer enhanced the AUC PMID: 19003994
28. PSA and kallikrein 2 transcripts in the peripheral blood of prostate cancer patients during barchytherapy could serve as a predictor of biochemiacl outcome. PMID: 19434652
29. Observational study of gene-disease association, gene-gene interaction, and genetic testing. (HuGE Navigator) PMID: 19223501
顯示更多

收起更多
蛋白家族：

Peptidase S1 family, Kallikrein subfamily
數據庫鏈接：

HGNC: 6363

OMIM: 147960

KEGG: hsa:3817

STRING: 9606.ENSP00000313581

UniGene: Hs.515560

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human